Review ArticleNarrative Review

Diffuse Cystic Lung Diseases

Baha Obaidat, Dina Yazdani, Kathryn A Wikenheiser-Brokamp and Nishant Gupta
Respiratory Care January 2020, 65 (1) 111-126; DOI: https://doi.org/10.4187/respcare.07117

References

  1. 1.↵
    1. Gupta N,
    2. Vassallo R,
    3. Wikenheiser-Brokamp KA,
    4. McCormack FX
    . Diffuse cystic lung disease. Part I. Am J Respir Crit Care Med 2015;191(12):1354–1366.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Hansell DM,
    2. Bankier AA,
    3. MacMahon H,
    4. McLoud TC,
    5. Müller NL,
    6. Remy J
    . Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246(3):697–722.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kikuchi E,
    2. Kinoshita I,
    3. Yamazaki K,
    4. Itoh T,
    5. Shimizu T,
    6. Shimizu H,
    7. Nishimura M
    . Epithelioid sarcoma presenting as pulmonary cysts with cancer antigen 125 expression. Respirology 2006;11(6):826–829.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ohdama S,
    2. Akagawa S,
    3. Matsubara O,
    4. Yoshizawa Y
    . Primary diffuse alveolar septal amyloidosis with multiple cysts and calcification. Eur Respir J 1996;9(7):1569–1571.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Colombat M,
    2. Caudroy S,
    3. Lagonotte E,
    4. Mal H,
    5. Danel C,
    6. Stern M,
    7. et al
    . Pathomechanisms of cyst formation in pulmonary light chain deposition disease. Eur Respir J 2008;32(5):1399–1403.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Taveira-DaSilva AM,
    2. Moss J
    . Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 2015;7:249–257.
    OpenUrl
  7. 7.↵
    1. Ciftci AO,
    2. Sanlialp I,
    3. Tanyel FC,
    4. Buyukpamukçu N
    . The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity. Respiration 2007;74(3):335–337.
    OpenUrlPubMed
  8. 8.↵
    1. Ho TB,
    2. Hull JH,
    3. Hughes NC
    . An 86-year-old female with lymphangioleiomyomatosis. Eur Respir J 2006;28(5):1065.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Crino PB,
    2. Nathanson KL,
    3. Henske EP
    . The tuberous sclerosis complex. N Engl J Med 2006;355(13):1345–1356.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Harknett EC,
    2. Chang WY,
    3. Byrnes S,
    4. Johnson J,
    5. Lazor R,
    6. Cohen MM,
    7. et al
    . Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011;104(11):971–979.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Slingerland JM,
    2. Grossman RF,
    3. Chamberlain D,
    4. Tremblay CE
    . Pulmonary manifestations of tuberous sclerosis in first degree relatives. Thorax 1989;44(3):212–214.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Rosner M,
    2. Hanneder M,
    3. Siegel N,
    4. Valli A,
    5. Hengstschläger M
    . The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008;658(3):234–246.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Sengupta S,
    2. Peterson TR,
    3. Sabatini DM
    . Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40(2):310–322.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Henske EP,
    2. McCormack FX
    . Lymphangioleiomyomatosis: a wolf in sheep's clothing. J Clin Invest 2012;122(11):3807–3816.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Henske EP
    . Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38(4):376–381.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Krymskaya VP,
    2. Shipley JM
    . Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003;28(5):546–550.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.
    1. Zhe X,
    2. Yang Y,
    3. Jakkaraju S,
    4. Schuger L
    . Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003;28(4):504–511.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Dongre A,
    2. Clements D,
    3. Fisher AJ,
    4. Johnson SR
    . Cathepsin K in lymphangioleiomyomatosis: LAM cell-fibroblast interactions enhance protease activity by extracellular acidification. Am J Pathol 2017;187(8):1750–1762.
    OpenUrl
  19. 19.↵
    1. Hayashi T,
    2. Kumasaka T,
    3. Mitani K,
    4. Terao Y,
    5. Watanabe M,
    6. Oide T,
    7. et al
    . Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 2011;35(12):1776–1785.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Li C,
    2. Lee PS,
    3. Sun Y,
    4. Gu X,
    5. Zhang E,
    6. Guo Y,
    7. et al
    . Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med 2014;211(1):15–28.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Yu JJ,
    2. Robb VA,
    3. Morrison TA,
    4. Ariazi EA,
    5. Karbowniczek M,
    6. Astrinidis A,
    7. et al
    . Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106(8):2635–2640.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Steagall WK,
    2. Glasgow CG,
    3. Hathaway OM,
    4. Avila NA,
    5. Taveira-Dasilva AM,
    6. Rabel A,
    7. et al
    . Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007;293(3):L800–L808.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Taveira-DaSilva AM,
    2. Stylianou MP,
    3. Hedin CJ,
    4. Kristof AS,
    5. Avila NA,
    6. Rabel A,
    7. et al
    . Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003;168(12):1427–1431.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Taveira-DaSilva AM,
    2. Stylianou MP,
    3. Hedin CJ,
    4. Hathaway O,
    5. Moss J
    . Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004;126(6):1867–1874.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Cohen MM,
    2. Pollock-BarZiv S,
    3. Johnson SR
    . Emerging clinical picture of lymphangioleiomyomatosis. Thorax 2005;60(10):875–879.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Hayashida M,
    2. Seyama K,
    3. Inoue Y,
    4. Fujimoto K,
    5. Kubo K
    , Respiratory Failure Research Group of the Japanese Ministry of Health, Labor, and Welfare. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 2007;12(4):523–530.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Gupta N,
    2. Lee HS,
    3. Ryu JH,
    4. Taveira-DaSilva AM,
    5. Beck GJ,
    6. Lee JC,
    7. et al
    . The NHLBI LAM registry: prognostic physiologic and radiologic biomarkers emerge from a 15-year prospective longitudinal analysis. Chest 2019;155(2):288–296.
    OpenUrl
  28. 28.↵
    1. Merchant RN,
    2. Pearson MG,
    3. Rankin RN,
    4. Morgan WK
    . Computerized tomography in the diagnosis of lymphangioleiomyomatosis. Am Rev Respir Dis 1985;131(2):295–297.
    OpenUrlPubMedWeb of Science
  29. 29.
    1. Avila NA,
    2. Chen CC,
    3. Chu SC,
    4. Wu M,
    5. Jones EC,
    6. Neumann RD,
    7. Moss J
    . Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000;214(2):441–446.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Avila NA,
    2. Kelly JA,
    3. Dwyer AJ,
    4. Johnson DL,
    5. Jones EC,
    6. Moss J
    . Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002;223(1):189–197.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Harari S,
    2. Torre O,
    3. Moss J
    . Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 2011;20(119):34–44.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Avila NA,
    2. Kelly JA,
    3. Chu SC,
    4. Dwyer AJ,
    5. Moss J
    . Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000;216(1):147–153.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    1. Matsui K,
    2. Tatsuguchi A,
    3. Valencia J,
    4. Yu Z,
    5. Bechtle J,
    6. Beasley MB,
    7. et al
    . Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000;31(10):1242–1248.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Ryu JH,
    2. Moss J,
    3. Beck GJ,
    4. Lee JC,
    5. Brown KK,
    6. Chapman JT,
    7. et al
    . The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173(1):105–111.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Urban T,
    2. Lazor R,
    3. Lacronique J,
    4. Murris M,
    5. Labrune S,
    6. Valeyre D,
    7. Cordier JF
    . Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 1999;78(5):321–337.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Kumasaka T,
    2. Seyama K,
    3. Mitani K,
    4. Souma S,
    5. Kashiwagi S,
    6. Hebisawa A,
    7. et al
    . Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005;29(10):1356–1366.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Matsumoto Y,
    2. Horiba K,
    3. Usuki J,
    4. Chu SC,
    5. Ferrans VJ,
    6. Moss J
    . Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21(3):327–336.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Gao L,
    2. Yue MM,
    3. Davis J,
    4. Hyjek E,
    5. Schuger L
    . In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch 2014;464(4):495–503.
    OpenUrlPubMed
  39. 39.↵
    1. Hagaman JT,
    2. Schauer DP,
    3. McCormack FX,
    4. Kinder BW
    . Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med 2010;181(12):1376–182.
    OpenUrlCrossRefPubMed
  40. 40.
    1. Northrup H,
    2. Krueger DA
    , Group ITSCC. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49(4):243–254.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Ryu JH,
    2. Hartman TE,
    3. Torres VE,
    4. Decker PA
    . Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest 2012;141(1):163–168.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Krueger DA,
    2. Northrup H,
    3. Group ITSCC
    . Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49(4):255–265.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Johnson SR,
    2. Cordier JF,
    3. Lazor R,
    4. Cottin V,
    5. Costabel U,
    6. Harari S,
    7. et al
    . European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35(1):14–26.
    OpenUrlFREE Full Text
  44. 44.↵
    1. McCormack FX,
    2. Gupta N,
    3. Finlay GR,
    4. Young LR,
    5. Taveira-DaSilva AM,
    6. Glasgow CG,
    7. et al
    . Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med 2016;194(6):748–761.
    OpenUrl
  45. 45.
    1. Young LR,
    2. Inoue Y,
    3. McCormack FX
    . Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008;358(2):199–200.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Young LR,
    2. Vandyke R,
    3. Gulleman PM,
    4. Inoue Y,
    5. Brown KK,
    6. Schmidt LS,
    7. et al
    . Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138(3):674–681.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Harari S,
    2. Torre O,
    3. Cassandro R,
    4. Taveira-DaSilva AM,
    5. Moss J
    . Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 2012;106(9):1286–1292.
    OpenUrlCrossRefPubMed
  48. 48.
    1. Meraj R,
    2. Wikenheiser-Brokamp KA,
    3. Young LR,
    4. Byrnes S,
    5. McCormack FX
    . Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med 2012;6(4):395–405.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Koba T,
    2. Arai T,
    3. Kitaichi M,
    4. Kasai T,
    5. Hirose M,
    6. Tachibana K,
    7. et al
    . Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a report of 24 consecutive patients. Respirology 2018;23(3):331–338.
    OpenUrl
  50. 50.↵
    1. Gupta N,
    2. Finlay GA,
    3. Kotloff RM,
    4. Strange C,
    5. Wilson KC,
    6. Young LR,
    7. et al
    . Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med 2017;196(10):1337–1348.
    OpenUrl
  51. 51.↵
    1. McCormack FX,
    2. Inoue Y,
    3. Moss J,
    4. Singer LG,
    5. Strange C,
    6. Nakata K,
    7. et al
    . Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364(17):1595–1606.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Lu C,
    2. Lee HS,
    3. Pappas GP,
    4. Dilling DF,
    5. Burger CD,
    6. Shifren A,
    7. et al
    . A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis. Ann Am Thorac Soc 2017;14(6):919–928.
    OpenUrl
  53. 53.↵
    1. El-Chemaly S,
    2. Taveira-Dasilva A,
    3. Goldberg HJ,
    4. Peters E,
    5. Haughey M,
    6. Bienfang D,
    7. et al
    . Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase i clinical trial. Chest 2017;151(6):1302–1310.
    OpenUrl
  54. 54.↵
    1. Almoosa KF,
    2. Ryu JH,
    3. Mendez J,
    4. Huggins JT,
    5. Young LR,
    6. Sullivan EJ,
    7. et al
    . Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006;129(5):1274–1281.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Weill D,
    2. Benden C,
    3. Corris PA,
    4. Dark JH,
    5. Davis RD,
    6. Keshavjee S,
    7. et al
    . A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34(1):1–15.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Kpodonu J,
    2. Massad MG,
    3. Chaer RA,
    4. Caines A,
    5. Evans A,
    6. Snow NJ,
    7. Geha AS
    . The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005;24(9):1247–1253.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Ussavarungsi K,
    2. Hu X,
    3. Scott JP,
    4. Erasmus DB,
    5. Mallea JM,
    6. Alvarez F,
    7. et al
    . Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis. Respir Med 2015;109(10):1354–1359.
    OpenUrl
  58. 58.↵
    1. Oprescu N,
    2. McCormack FX,
    3. Byrnes S,
    4. Kinder BW
    . Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung 2013;191(1):35–42.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Taveira-DaSilva AM,
    2. Pacheco-Rodriguez G,
    3. Moss J
    . The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol 2010;8(1):9–19.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Taveira-DaSilva AM,
    2. Hedin C,
    3. Stylianou MP,
    4. Travis WD,
    5. Matsui K,
    6. Ferrans VJ,
    7. Moss J
    . Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001;164(6):1072–1076.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Young L,
    2. Lee HS,
    3. Inoue Y,
    4. Moss J,
    5. Singer LG,
    6. Strange C,
    7. et al
    . Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013;1(6):445–452.
    OpenUrl
  62. 62.↵
    1. Gupta N,
    2. Lee HS,
    3. Young LR,
    4. Strange C,
    5. Moss J,
    6. Singer LG,
    7. et al
    . Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J 2019;53(4):1802066.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Howarth DM,
    2. Gilchrist GS,
    3. Mullan BP,
    4. Wiseman GA,
    5. Edmonson JH,
    6. Schomberg PJ
    . Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999;85(10):2278–2290.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Tazi A,
    2. Bonay M,
    3. Bergeron A,
    4. Grandsaigne M,
    5. Hance AJ,
    6. Soler P
    . Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X. Thorax 1996;51(6):611–614.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Tazi A,
    2. Moreau J,
    3. Bergeron A,
    4. Dominique S,
    5. Hance AJ,
    6. Soler P
    . Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 1999;163(6):3511–3515.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Sahm F,
    2. Capper D,
    3. Preusser M,
    4. Meyer J,
    5. Stenzinger A,
    6. Lasitschka F,
    7. et al
    . BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120(12):e28–e34.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Vassallo R,
    2. Ryu JH,
    3. Schroeder DR,
    4. Decker PA,
    5. Limper AH
    . Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002;346(7):484–490.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Abbott GF,
    2. Rosado-de-Christenson ML,
    3. Franks TJ,
    4. Frazier AA,
    5. Galvin JR
    . From the archives of the AFIP: pulmonary Langerhans cell histiocytosis. Radiographics 2004;24(3):821–841.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Krajicek BJ,
    2. Ryu JH,
    3. Hartman TE,
    4. Lowe VJ,
    5. Vassallo R
    . Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009;135(6):1542–1549.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Sholl LM,
    2. Hornick JL,
    3. Pinkus JL,
    4. Pinkus GS,
    5. Padera RF
    . Immunohistochemical analysis of Langerin in Langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. Am J Surg Pathol 2007;31(6):947–952.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Baqir M,
    2. Vassallo R,
    3. Maldonado F,
    4. Yi ES,
    5. Ryu JH
    . Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013;20(4):309–312.
    OpenUrl
  72. 72.↵
    1. Ninaber M,
    2. Dik H,
    3. Peters E
    . Complete pathological resolution of pulmonary Langerhans cell histiocytosis. Respirol Case Rep 2014;2(2):76–78.
    OpenUrl
  73. 73.
    1. Mogulkoc N,
    2. Veral A,
    3. Bishop PW,
    4. Bayindir U,
    5. Pickering CA,
    6. Egan JJ
    . Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999;115(5):1452–1455.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    1. Sawalha L,
    2. Kumar A,
    3. Arshad A,
    4. Mador MJ
    . Pulmonary Langerhans cell histiocytosis: radiologic resolution following cessation of second hand smoking. Clin Respir J 2017;11(6):1063–1067.
    OpenUrl
  75. 75.↵
    1. Tazi A,
    2. Marc K,
    3. Dominique S,
    4. de Bazelaire C,
    5. Crestani B,
    6. Chinet T,
    7. et al
    . Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis. Eur Respir J 2012;40(4):905–912.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Grobost V,
    2. Khouatra C,
    3. Lazor R,
    4. Cordier JF,
    5. Cottin V
    . Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 2014;9:191.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Lorillon G,
    2. Bergeron A,
    3. Detourmignies L,
    4. Jouneau S,
    5. Wallaert B,
    6. Frija J,
    7. Tazi A
    . Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2012;186(9):930–932.
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    1. Lorillon G,
    2. Jouenne F,
    3. Baroudjian B,
    4. de Margerie-Mellon C,
    5. Vercellino L,
    6. Meignin V,
    7. et al
    . Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion. Am J Respir Crit Care Med 2018;198(5):675–678.
    OpenUrl
  79. 79.↵
    1. Mendez JL,
    2. Nadrous HF,
    3. Vassallo R,
    4. Decker PA,
    5. Ryu JH
    . Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004;125(3):1028–1032.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    1. Dauriat G,
    2. Mal H,
    3. Thabut G,
    4. Mornex JF,
    5. Bertocchi M,
    6. Tronc F,
    7. et al
    . Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006;81(5):746–750.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    1. Delobbe A,
    2. Durieu J,
    3. Duhamel A,
    4. Wallaert B
    . Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J 1996;9(10):2002–2006.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    1. Chaowalit N,
    2. Pellikka PA,
    3. Decker PA,
    4. Aubry MC,
    5. Krowka MJ,
    6. Ryu JH,
    7. Vassallo R
    . Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004;79(10):1269–1275.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Le Pavec J,
    2. Lorillon G,
    3. Jaïs X,
    4. Tcherakian C,
    5. Feuillet S,
    6. Dorfmüller P,
    7. et al
    . Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012;142(5):1150–1157.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    1. Tazi A,
    2. de Margerie C,
    3. Naccache JM,
    4. Fry S,
    5. Dominique S,
    6. Jouneau S,
    7. et al
    . The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis 2015;10:30.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Kunogi M,
    2. Kurihara M,
    3. Ikegami TS,
    4. Kobayashi T,
    5. Shindo N,
    6. Kumasaka T,
    7. et al
    . Clinical and genetic spectrum of Birt-Hogg-Dube syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. J Med Genet 2010;47(4):281–287.
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    1. Toro JR,
    2. Pautler SE,
    3. Stewart L,
    4. Glenn GM,
    5. Weinreich M,
    6. Toure O,
    7. et al
    . Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med 2007;175(10):1044–1053.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    1. Kumasaka T,
    2. Hayashi T,
    3. Mitani K,
    4. Kataoka H,
    5. Kikkawa M,
    6. Tobino K,
    7. et al
    . Characterization of pulmonary cysts in Birt-Hogg-Dubé syndrome: histopathological and morphometric analysis of 229 pulmonary cysts from 50 unrelated patients. Histopathology 2014;65(1):100–110.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.
    1. Goncharova EA,
    2. Goncharov DA,
    3. James ML,
    4. Atochina-Vasserman EN,
    5. Stepanova V,
    6. Hong SB,
    7. et al
    . Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. Cell Rep 2014;7(2):412–423.
    OpenUrlCrossRefPubMedWeb of Science
  89. 89.
    1. Khabibullin D,
    2. Medvetz DA,
    3. Pinilla M,
    4. Hariharan V,
    5. Li C,
    6. Hergrueter A,
    7. et al
    . Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. Physiol Rep 2014;2(8):e12107.
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Furuya M,
    2. Tanaka R,
    3. Koga S,
    4. Yatabe Y,
    5. Gotoda H,
    6. Takagi S,
    7. et al
    . Pulmonary cysts of Birt-Hogg-Dubé syndrome: a clinicopathologic and immunohistochemical study of 9 families. Am J Surg Pathol 2012;36(4):589–600.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Toro JR,
    2. Wei MH,
    3. Glenn GM,
    4. Weinreich M,
    5. Toure O,
    6. Vocke C,
    7. et al
    . BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008;45(6):321–331.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Gupta N,
    2. Kopras EJ,
    3. Henske EP,
    4. James LE,
    5. El-Chemaly S,
    6. Veeraraghavan S,
    7. et al
    . Spontaneous pneumothoraces in patients with Birt-Hogg-Dubé syndrome. Ann Am Thorac Soc 2017;14(5):706–713.
    OpenUrl
  93. 93.↵
    1. Onuki T,
    2. Goto Y,
    3. Kuramochi M,
    4. Inagaki M,
    5. Bhunchet E,
    6. Suzuki K,
    7. et al
    . Radiologically indeterminate pulmonary cysts in Birt-Hogg-Dubé syndrome. Ann Thorac Surg 2014;97(2):682–685.
    OpenUrl
  94. 94.↵
    1. Tobino K,
    2. Hirai T,
    3. Johkoh T,
    4. Kurihara M,
    5. Fujimoto K,
    6. Tomiyama N,
    7. et al
    . Differentiation between Birt-Hogg-Dubé syndrome and lymphangioleiomyomatosis: quantitative analysis of pulmonary cysts on computed tomography of the chest in 66 females. Eur J Radiol 2012;81(6):1340–1346.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Aivaz O,
    2. Berkman S,
    3. Middelton L,
    4. Linehan WM,
    5. DiGiovanna JJ,
    6. Cowen EW
    . Comedonal and cystic fibrofolliculomas in Birt-Hogg-Dube syndrome. JAMA Dermatol 2015;151(7):770–774.
    OpenUrl
  96. 96.↵
    1. Pavlovich CP,
    2. Grubb RL,
    3. Hurley K,
    4. Glenn GM,
    5. Toro J,
    6. Schmidt LS,
    7. et al
    . Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005;173(5):1482–1486.
    OpenUrlCrossRefPubMedWeb of Science
  97. 97.↵
    1. Tobino K,
    2. Gunji Y,
    3. Kurihara M,
    4. Kunogi M,
    5. Koike K,
    6. Tomiyama N,
    7. et al
    . Characteristics of pulmonary cysts in Birt-Hogg-Dubé syndrome: thin-section CT findings of the chest in 12 patients. Eur J Radiol 2011;77(3):403–409.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Gupta N,
    2. Seyama K,
    3. McCormack FX
    . Pulmonary manifestations of Birt-Hogg-Dubé syndrome. Fam Cancer 2013;12(3):387–396.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.↵
    1. Menko FH,
    2. van Steensel MA,
    3. Giraud S,
    4. Friis-Hansen L,
    5. Richard S,
    6. Ungari S,
    7. et al
    . Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009;10(12):1199–206.
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Gupta N,
    2. Langenderfer D,
    3. McCormack FX,
    4. Schauer DP,
    5. Eckman MH
    . Chest computed tomographic image screening for cystic lung diseases in patients with spontaneous pneumothorax is cost effective. Ann Am Thorac Soc 2017;14(1):17–25.
    OpenUrl
  101. 101.↵
    1. Stamatakis L,
    2. Metwalli AR,
    3. Middelton LA,
    4. Marston Linehan W
    . Diagnosis and management of BHD-associated kidney cancer. Fam Cancer 2013;12(3):397–402.
    OpenUrlPubMed
  102. 102.↵
    1. Nicholson AG
    . Lymphocytic interstitial pneumonia and other lymphoproliferative disorders in the lung. Semin Respir Crit Care Med 2001;22(4):409–422.
    OpenUrlCrossRefPubMedWeb of Science
  103. 103.↵
    1. Guinee DG
    . Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities. Arch Pathol Lab Med 2010;134(5):691–701.
    OpenUrlPubMed
  104. 104.↵
    1. Cha SI,
    2. Fessler MB,
    3. Cool CD,
    4. Schwarz MI,
    5. Brown KK
    . Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006;28(2):364–369.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    1. Hare SS,
    2. Souza CA,
    3. Bain G,
    4. Seely JM,
    5. Gomes MM,
    6. Quigley M
    . The radiological spectrum of pulmonary lymphoproliferative disease. Br J Radiol 2012;85(1015):848–864.
    OpenUrlAbstract/FREE Full Text
  106. 106.↵
    1. Gupta N,
    2. Wikenheiser-Brokamp KA,
    3. Fischer A,
    4. McCormack FX
    . Diffuse cystic lung disease as the presenting manifestation of Sjögren syndrome. Ann Am Thorac Soc 2016;13(3):371–375.
    OpenUrl
  107. 107.↵
    1. Swigris JJ,
    2. Berry GJ,
    3. Raffin TA,
    4. Kuschner WG
    . Lymphoid interstitial pneumonia: a narrative review. Chest 2002;122(6):2150–2164.
    OpenUrlCrossRefPubMedWeb of Science
  108. 108.↵
    1. Johkoh T,
    2. Ichikado K,
    3. Akira M,
    4. Honda O,
    5. Tomiyama N,
    6. Mihara N,
    7. et al
    . Lymphocytic interstitial pneumonia: follow-up CT findings in 14 patients. J Thorac Imaging 2000;15(3):162–167.
    OpenUrlCrossRefPubMedWeb of Science
  109. 109.↵
    1. Dufour V,
    2. Wislez M,
    3. Bergot E,
    4. Mayaud C,
    5. Cadranel J
    . Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003;36(10):e127–e130.
    OpenUrlCrossRefPubMed
  110. 110.↵
    1. Chew KM,
    2. Clarke MJ,
    3. Dubey N,
    4. Seet JE
    . Nodular pulmonary amyloidosis with unusual, widespread lung cysts. Singapore Med J 2013;54(5):e97–e99.
    OpenUrl
  111. 111.↵
    1. Baqir M,
    2. Kluka EM,
    3. Aubry MC,
    4. Hartman TE,
    5. Yi ES,
    6. Bauer PR,
    7. Ryu JH
    . Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med 2013;107(4):616–621.
    OpenUrlCrossRefPubMed
  112. 112.↵
    1. Randall RE,
    2. Williamson WC,
    3. Mullinax F,
    4. Tung MY,
    5. Still WJ
    . Manifestations of systemic light chain deposition. Am J Med 1976;60(2):293–299.
    OpenUrlCrossRefPubMedWeb of Science
  113. 113.↵
    1. Buxbaum J,
    2. Gallo G
    . Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999;13(6):1235–1248.
    OpenUrlCrossRefPubMedWeb of Science
  114. 114.↵
    1. Colombat M,
    2. Stern M,
    3. Groussard O,
    4. Droz D,
    5. Brauner M,
    6. Valeyre D,
    7. et al
    . Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med 2006;173(7):777–780.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.
    1. Girard N,
    2. Vasiljevic A,
    3. Cottin V,
    4. Falchero L,
    5. Meyronet D,
    6. Thivolet-Bejui F,
    7. Cordier JF
    . Respiratory failure with diffuse bronchiectases and cryoglobulinaemia. Eur Respir J 2008;31(6):1374–1378.
    OpenUrlFREE Full Text
  116. 116.↵
    1. Hirschi S,
    2. Colombat M,
    3. Kessler R,
    4. Reynaud-Gaubert M,
    5. Stern M,
    6. Chenard MP,
    7. et al
    . Lung transplantation for advanced cystic lung disease due to nonamyloid kappa light chain deposits. Ann Am Thorac Soc 2014;11(7):1025–1031.
    OpenUrlCrossRefPubMed
  117. 117.
    1. Gupta N,
    2. Vassallo R,
    3. Wikenheiser-Brokamp KA,
    4. McCormack FX
    . Diffuse cystic lung disease. Part II. Am J Respir Crit Care Med 2015;192(1):17–29.
    OpenUrlCrossRefPubMed
  118. 118.
    1. Dziegiel P,
    2. Dolilńska-Krajewska B,
    3. Dumańska M,
    4. Wecławek J,
    5. Jeleń M,
    6. Podhorska-Okołów M,
    7. et al
    . Coexpression of CD1a, Langerin and Birbeck's granules in Langerhans cell histiocytoses (LCH) in children: ultrastructural and immunocytochemical studies. Folia Histochem Cytobiol 2007;45(1):21–25.
    OpenUrlPubMed
  119. 119.
    1. Cooley J,
    2. Lee YCG,
    3. Gupta N
    . Spontaneous pneumothorax in diffuse cystic lung diseases. Curr Opin Pulm Med 2017;23(4):323–333.
    OpenUrl
  120. 120.
    1. Pollock-BarZiv S,
    2. Cohen MM,
    3. Downey GP,
    4. Johnson SR,
    5. Sullivan E,
    6. McCormack FX
    . Air travel in women with lymphangioleiomyomatosis. Thorax 2007;62(2):176–180.
    OpenUrlAbstract/FREE Full Text
  121. 121.
    1. Johannesma PC,
    2. van de Beek I,
    3. van der Wel JW,
    4. Paul MA,
    5. Houweling AC,
    6. Jonker MA,
    7. et al
    . Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome. Springerplus 2016;5(1):1506.
    OpenUrl
  122. 122.
    1. MacDuff A,
    2. Arnold A,
    3. Harvey J,
    4. Group BPDG
    . Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl 2):ii18–ii31.
    OpenUrlFREE Full Text
  123. 123.
    1. Singla A,
    2. Kopras EJ,
    3. McCormack FX,
    4. Gupta N
    . Management of spontaneous pneumothorax and safety of air travel in patients with pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2017;2017;195:A1591.
    OpenUrl
  124. 124.
    1. Wajda N,
    2. Gupta N
    . Air travel-related spontaneous pneumothorax in diffuse cystic lung diseases. Curr Pulmonol Rep 2018;7(2):56–62.
    OpenUrl
  125. 125.
    1. Bahmer T,
    2. Watz H,
    3. Waschki B,
    4. Gramm M,
    5. Magnussen H,
    6. Rabe KF,
    7. et al
    . Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. Thorax 2016;71(7):662–663.
    OpenUrlAbstract/FREE Full Text
  126. 126.
    1. Araujo MS,
    2. Baldi BG,
    3. Freitas CS,
    4. Albuquerque AL,
    5. Marques da Silva CC,
    6. Kairalla RA,
    7. Carvalho CR
    . Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. Eur Respir J 2016;47(5):1452–1460.
    OpenUrlAbstract/FREE Full Text
  127. 127.
    1. Taveira-DaSilva AM,
    2. Julien-Williams P,
    3. Jones AM,
    4. Moss J
    . Incidence of pneumothorax in patients with lymphangioleiomyomatosis undergoing pulmonary function and exercise testing. Chest 2016;150(1):e5–e8.
    OpenUrl
  128. 128.
    1. Cooper BG
    . An update on contraindications for lung function testing. Thorax 2011;66(8):714–723.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords